As clinical trial researchers and treatment providers since 1974, we believe that the major need within the field of addiction is for a working partnership between leaders in the research and in the treatment provider community. This partnership should elevate the standards of both treatment and research in this field. To this end we have Philadelphia metropolitan statistical area as part of the NIDA Clinical Trials Network. We have recruited and cultivated collaborative relationships with seven of the very best organizations representing 60 treatment programs from this region; those with distinguished records in training and a record of community leadership. All the programs that have joined our cooperative have participated in multiple research projects over the past ten years and each program has empirical evidence of high quality treatment through prior, independent evaluations. Thus, our Cooperative has been constructed as a consortium of excellence in treatment, research and education. In this proposal we provide evidence that our Cooperative can contribute to the broader goals of changing the way addiction treatment is taught, practiced and perceived. Specifically, we will: * Direct at least one research study each year from one of three areas: 1. Controlled clinical trials of medications. 2. Controlled clinical trials of behavioral and psychosocial treatments. 3. Health Services and Practice studies of treatment access, financing and organization. * Participate in at least two additional research studies each year from the three areas. * Develop two important training and technology transfer skills. 1. Train new and existing professionals in the delivery, management and monitoring of the improved treatment methods. 2. Implement into standard practice within our Cooperative at least two medications and at least two behavioral therapies-by the end of the fifth year we will also have implemented at least one medication and one behavioral therapy into standard practice in programs outside the cooperative. * Represent the field of addiction to the world of providers, payers and policy makers, supporting medications and treatments that have been validated by the CTN.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013043-05S2
Application #
6895948
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Levy, Janet
Project Start
1999-09-30
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2005-08-31
Support Year
5
Fiscal Year
2004
Total Cost
$249,889
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69
Hser, Yih-Ing; Evans, Elizabeth; Huang, David et al. (2016) Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111:695-705
Poole, Sabrina A; Pecoraro, Anna; Subramaniam, Geetha et al. (2016) Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence. J Addict Med 10:26-33
Campbell, Aimee N C; Brooks, Audrey J; Pavlicova, Martina et al. (2016) Barriers to Condom Use: Results for Men and Women Enrolled in HIV Risk Reduction Trials in Outpatient Drug Treatment. J HIV AIDS Soc Serv 15:130-146
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Metsch, Lisa R; Feaster, Daniel J; Gooden, Lauren et al. (2016) Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. JAMA 316:156-70

Showing the most recent 10 out of 102 publications